Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

View All

Nov 17, 2020 • 7:30 AM EST

Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia

Nov 10, 2020 • 7:30 AM EST

Rigel to Present at the Jefferies Virtual London Healthcare Conference

Nov 5, 2020 • 4:01 PM EST

Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update

November 2020

View Presentation

Jefferies Virtual London Healthcare Conference

View Event View All

Q3 2020

Quarter Ended Sep 30, 2020

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080